Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 19, 2014

View Archived Issues

Genetic profiling of CTCs to determine drug response in SCLC

Rediscovery of a natural compound to combat multidrug resistance in bacteria

TAXIS Pharmaceuticals presents novel antibacterial agents targeting FtsZ

New potent and selective Wnt signaling inhibitor with in vivo activity

Coherus BioSciences' adalimumab biosimilar shows pharmacokinetic similarity to Humira

Canadian government donates experimental Ebola vaccine to the WHO

HUYA partners with Changzhou Center for Biotech Development to progress Chinese drug development

Eisai proton pump inhibitor licensed by Zeria in Japan

Achillion reports interim data from phase II trial of ACH-3102 and sofosbuvir in HCV infection

Novel HPLC system measures serum apoE-HDLc

GlaxoSmithKline discloses new PAF acetylhydrolase inhibitors

Novel antiviral agents patented by Roche

Merck & Co. presents novel BTK inhibitors

Naurex discloses novel NMDA receptor modulators

Ampio Pharmaceuticals reports data from multiple-injection study of Ampion

Photocure provides update on partnership for Lumacan

Provectus signs agreement with Sinopharm-CSIPI and Sinopharm A-THINK Pharmaceutical

Clinical study of TG-1101, TGR-1202 and ibrutinib for CLL

Biogen Idec discloses novel S1P5 receptor modulators

Pfizer submits NDA for palbociclib to the FDA

NIH awards grant to Sedia Biosciences for rapid HIV-1 incidence assay

Eisai seeks approval for lenvatinib in Europe and the U.S.

Amarantus gains rights to MANF for retinal diseases from University of Miami

Sanofi and PATH deliver first antimalarial produced using semisynthetic artemisinin

Eli Lilly and Boehringer Ingelheim's insulin glargine receives tentative approval from the FDA

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 27, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
Sichuan Kelun Pharmaceutical Research Institute discovers GPR6 inverse agonists
BioWorld Science
Sichuan Kelun Pharmaceutical Research Institute Co. Ltd. has identified G protein-coupled receptor 6 (GPR6) inverse agonists reported to be useful for the...
Pharma industry faces long haul to get return on investment from AI
BioWorld Science
Artificial intelligence tools are springing up at multiple points along drug discovery and development, but despite the hype, as yet there is minimal return on...